5-HT 6 Receptor Ligands and their Antipsychotic Potential

International Review of Neurobiology

Volumn 96, Issue , 2011, Pages 141-161

  Arnt, Jørn ^a   Olsen, Christina Kurre ^a  

^a H LUNDBECK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

3 PHENYLSULFONYL 8 (1 PIPERAZINYL)QUINOLINE; 4 AMINO N [2,6 BIS(METHYLAMINO) 4 PYRIMIDINYL]BENZENESULFONAMIDE; 5 CHLORO N [4 METHOXY 3 (1 PIPERAZINYL)PHENYL] 3 METHYL 2 BENZOTHIOPHENESULFONAMIDE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; CLOZAPINE; DIZOCILPINE; DOPAMINE; E 6801; HALOPERIDOL; LU AE 58054; N (3,5 DICHLORO 2 METHOXYPHENYL) 4 METHOXY 3 (1 PIPERAZINYL)BENZENESULFONAMIDE; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; RO 43 68554; SB 258510A; SB 258585; SEROTONIN 6 ANTAGONIST; SEROTONIN 6 RECEPTOR; SEROTONIN AGONIST; SERTINDOLE; UNCLASSIFIED DRUG; VOLINANSERIN; WAY 181187; LIGAND; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR;

ACUTE DRUG ADMINISTRATION; ADD ON THERAPY; ANIMAL BEHAVIOR; ARTICLE; CATALEPSY; CHRONIC DRUG ADMINISTRATION; COGNITIVE DEFECT; COMBINATION CHEMOTHERAPY; DISEASE ASSOCIATION; DISEASE MODEL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG PENETRATION; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG TREATMENT FAILURE; HUMAN; HYPERACTIVITY; LEARNING DISORDER; MONOTHERAPY; MOTOR DYSFUNCTION; NEGATIVE SYNDROME; NONHUMAN; POSITIVE SYNDROME; PREPULSE INHIBITION; PRIORITY JOURNAL; PROTEIN FUNCTION; PSYCHOPHARMACOLOGY; RECEPTOR OCCUPANCY; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; SYMPTOMATOLOGY; ANIMAL; BRAIN LEVEL; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOSIS; REVIEW;

ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN CHEMISTRY; DISEASE MODELS, ANIMAL; HUMANS; LIGANDS; PSYCHOTIC DISORDERS; RECEPTORS, SEROTONIN; SEROTONIN ANTAGONISTS;

EID: 79951525244     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-385902-0.00006-1     Document Type: Chapter

References (77)

1. Abdul-Monim Z., Neill J.C., Reynolds G.P. Sub-chronic psychotomimetic phencyclidine induces deficits in reversal learning and alterations in parvalbumin-immunoreactive expression in the rat. J. Psychopharmacol. 2007, 21:198-205.
2. Abdul-Monim Z., Reynolds G.P., Neill J.C. The atypical antipsychotic ziprasidone, but not haloperidol, improves phencyclidine-induced cognitive deficits in a reversal learning task in the rat. J. Psychopharmacol. 2003, 17:57-65.
3. Abdul-Monim Z., Reynolds G.P., Neill J.C. The effect of atypical and classical antipsychotics on sub-chronic PCP-induced cognitive deficits in a reversal-learning paradigm. Behav. Brain Res. 2006, 169:263-273.
4. Arnt J. Pharmacological specificity of conditioned avoidance response inhibition in rats: inhibition by neuroleptics and correlation to dopamine receptor blockade. Acta Pharmacol. Toxicol. 1982, 51:321-329.
5. Arnt J. Differential effects of classical and newer antipsychotics on the hypermotility induced by two dose levels of d-amphetamine. Eur. J. Pharmacol. 1995, 283:55-62.
6. Arnt J., Bang-Andersen B., Bymaster F.P., Cohen M.P., DeLapp N.W., Giethlen B., Grayson B., Kreilgaard M., McKinzie D.L., Neill J., Nielsen S.M., Nelson D.L., Poulsen M.N., Schauss J.M., Witten L.M. Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine treatment in a novel object recognition test in rats. Int. J. Neuropsychopharmacol 2010, 13:1021-1033.
7. Arnt J., Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 1998, 18:63-101.
8. Bentley J.C., Bourson A., Boess F.G., Fone K.C., Marsden C.A., Petit N., Sleight A.J. Investigation of stretching behaviour induced by the selective 5-HT6 receptor antagonist, Ro 04-6790, in rats. Br. J. Pharmacol. 1999, 126:1537-1542.
9. Birrell J.M., Brown V.J. Medial frontal cortex mediates perceptual attentional set shifting in the rat. J. Neurosci. 2000, 20:4320-4324.
10. Bonasera S.J., Chu H.M., Brennan T.J., Tecott L.H. A null mutation of the serotonin 6 receptor alters acute responses to ethanol. Neuropsychopharmacology 2006, 31:1801-1813.
11. Bourson A., Boess F.G., Bos M., Sleight A.J. Involvement of 5-HT6 receptors in nigro-striatal function in rodents. Br. J. Pharmacol. 1998, 125:1562-1566.
12. Broberg B.V., Glenthoj B.Y., Dias R., Larsen D.B., Olsen C.K. Reversal of cognitive deficits by an ampakine (CX516) and sertindole in two animal models of schizophrenia-sub-chronic and early postnatal PCP treatment in attentional set-shifting. Psychopharmacology (Berl) 2009, 206:631-640.
13. Bunney B.S., Grace A.A. Acute and chronic haloperidol treatment: comparison of effects on nigral dopaminergic cell activity. Life Sci. 1978, 23:1715-1727.
14. Burnham K.E., Baxter M.G., Bainton J.R., Southam E., Dawson L.A., Bannerman D.M., Sharp T. Activation of 5-HT(6) receptors facilitates attentional set shifting. Psychopharmacology (Berl) 2010, 208:13-21.
15. Bymaster F.P., Falcone J.F., Bauzon D., Kennedy J.S., Schenck K., DeLapp N.W., Cohen M.L. Potent antagonism of 5-HT(3) and 5-HT(6) receptors by olanzapine. Eur. J. Pharmacol. 2001, 430:341-349.
16. Dawson L.A., Nguyen H.Q., Li P. The 5-HT(6) receptor antagonist SB-271046 selectively enhances excitatory neurotransmission in the rat frontal cortex and hippocampus. Neuropsychopharmacology 2001, 25:662-668.
17. Desbonnet L., Waddington J.L., Tuathaigh C.M. Mice mutant for genes associated with schizophrenia: common phenotype or distinct endophenotypes?. Behav. Brain Res. 2009, 204:258-273.
18. East S.Z., Burnet P.W., Leslie R.A., Roberts J.C., Harrison P.J. 5-HT6 receptor binding sites in schizophrenia and following antipsychotic drug administration: autoradiographic studies with [125I]SB-258585. Synapse 2002, 45:191-199.
19. Egerton A., Reid L., McGregor S., Cochran S.M., Morris B.J., Pratt J.A. Subchronic and chronic PCP treatment produces temporally distinct deficits in attentional set shifting and prepulse inhibition in rats. Psychopharmacology (Berl) 2008, 198:37-49.
20. Featherstone R.E., Rizos Z., Nobrega J.N., Kapur S., Fletcher P.J. Gestational methylazoxymethanol acetate treatment impairs select cognitive functions: parallels to schizophrenia. Neuropsychopharmacology 2007, 32:483-492.
21. Ferguson S.M., Mitchell E.S., Neumaier J.F. Increased expression of 5-HT6 receptors in the nucleus accumbens blocks the rewarding but not psychomotor activating properties of cocaine. Biol. Psychiatry 2008, 63:207-213.
22. Foley A.G., Hirst W.D., Gallagher H.C., Barry C., Hagan J.J., Upton N., Walsh F.S., Hunter A.J., Regan C.M. The selective 5-HT6 receptor antagonists SB-271046 and SB-399885 potentiate NCAM PSA immunolabeling of dentate granule cells, but not neurogenesis, in the hippocampal formation of mature Wistar rats. Neuropharmacology 2008, 54:1166-1174.
23. Fone K.C., Porkess M.V. Behavioural and neurochemical effects of post-weaning social isolation in rodents-relevance to developmental neuropsychiatric disorders. Neurosci. Biobehav. Rev. 2008, 32:1087-1102.
24. Frantz K.J., Hansson K.J., Stouffer D.G., Parsons L.H. 5-HT(6) receptor antagonism potentiates the behavioral and neurochemical effects of amphetamine but not cocaine. Neuropharmacology 2002, 42:170-180.
25. Geyer M.A. Developing translational animal models for symptoms of schizophrenia or bipolar mania. Neurotox. Res. 2008, 14:71-78.
26. Goetghebeur P., Dias R. Comparison of haloperidol, risperidone, sertindole, and modafinil to reverse an attentional set-shifting impairment following subchronic PCP administration in the rat - a back translational study. Psychopharmacology (Berl) 2009, 202:287-293.
27. Grace A.A., Bunney B.S., Moore H., Todd C.L. Dopamine-cell depolarization block as a model for the therapeutic actions of antipsychotic drugs. Trends Neurosci. 1997, 20:31-37.
28. Grayson B., Idris N.F., Neill J.C. Atypical antipsychotics attenuate a sub-chronic pcp-induced cognitive deficit in the novel object recognition task in the rat. Behav. Brain Res. 2007, 184:31-38.
29. Green M.F. Am. J. Psychiatry. Cognition, drug treatment, and functional outcome in schizophrenia: a tale of two transitions 2007, 164:992-994.
30. Hatcher P.D., Brown V.J., Tait D.S., Bate S., Overend P., Hagan J.J., Jones D.N. 5-HT6 receptor antagonists improve performance in an attentional set shifting task in rats. Psychopharmacology (Berl) 2005, 181:253-259.
31. Idris N., Neill J., Grayson B., Bang-Andersen B., Witten L.M., Brennum L.T., Arnt J. Sertindole improves sub-chronic PCP-induced reversal learning and episodic memory deficits in rodents: involvement of 5-HT(6) and 5-HT (2A) receptor mechanisms. Psychopharmacology (Berl) 2010, 208:23-36.
32. Idris N.F., Repeto P., Neill J.C., Large C.H. Investigation of the effects of lamotrigine and clozapine in improving reversal-learning impairments induced by acute phencyclidine and d-amphetamine in the rat. Psychopharmacology (Berl) 2005, 179:336-348.
33. Jentsch J.D., Roth R.H. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1999, 20:201-225.
34. Keefe R.S., Bilder R.M., Davis S.M., Harvey P.D., Palmer B.W., Gold J.M., Meltzer H.Y., Green M.F., Capuano G., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Davis C.E., Hsiao J.K., Lieberman J.A. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch. Gen. Psychiatry 2007, 64:633-647.
35. Kellendonk C., Simpson E.H., Kandel E.R. Modeling cognitive endophenotypes of schizophrenia in mice. Trends Neurosci. 2009, 32:347-358.
36. Kendall, I., Slotten, H. A., Codony, X., Burgueno, J., Pauwels, P. J., Vela, J. M., and Fone, K. C. (2010). E-6801, a 5-HT(6) receptor agonist, improves recognition memory by combined modulation of cholinergic and glutamatergic neurotransmission in the rat. Psychopharmacology (Berl) (Epub April 20). doi: 10.1007/s00213-010-1854-3.
37. King M.V., Sleight A.J., Woolley M.L., Topham I.A., Marsden C.A., Fone K.C. 5-HT6 receptor antagonists reverse delay-dependent deficits in novel object discrimination by enhancing consolidation - an effect sensitive to NMDA receptor antagonism. Neuropharmacology 2004, 47:195-204.
38. Kirby B.P., Waddington J.L., O'Tuathaigh C.M. Advancing a functional genomics for schizophrenia: psychopathological and cognitive phenotypes in mutants with gene disruption. Brain Res. Bull. 2009, 83:162-176.
39. Lacroix L.P., Dawson L.A., Hagan J.J., Heidbreder C.A. 5-HT6 receptor antagonist SB-271046 enhances extracellular levels of monoamines in the rat medial prefrontal cortex. Synapse 2004, 51:158-164.
40. Leng A., Ouagazzal A., Feldon J., Higgins G.A. Effect of the 5-HT6 receptor antagonists Ro04-6790 and Ro65-7199 on latent inhibition and prepulse inhibition in the rat: comparison to clozapine. Pharmacol. Biochem. Behav. 2003, 75:281-288.
41. Lewis D.A., Hashimoto T., Morris H.M. Cell and receptor type-specific alterations in markers of GABA neurotransmission in the prefrontal cortex of subjects with schizophrenia. Neurotox. Res. 2008, 14:237-248.
42. Lewis D.A., Moghaddam B. Cognitive dysfunction in schizophrenia: convergence of gamma-aminobutyric acid and glutamate alterations. Arch. Neurol. 2006, 63:1372-1376.
43. Li Z., Huang M., Prus A.J., Dai J., Meltzer H.Y. 5-HT6 receptor antagonist SB-399885 potentiates haloperidol and risperidone-induced dopamine efflux in the medial prefrontal cortex or hippocampus. Brain Res. 2007, 1134:70-78.
44. Lodge D.J., Behrens M.M., Grace A.A. A loss of parvalbumin-containing interneurons is associated with diminished oscillatory activity in an animal model of schizophrenia. J. Neurosci. 2009, 29:2344-2354.
45. Lodge D.J., Grace A.A. Gestational methylazoxymethanol acetate administration: a developmental disruption model of schizophrenia. Behav. Brain Res. 2009, 204:306-312.
46. Loiseau F., Dekeyne A., Millan M.J. Pro-cognitive effects of 5-HT6 receptor antagonists in the social recognition procedure in rats: implication of the frontal cortex. Psychopharmacology (Berl) 2008, 196:93-104.
47. McLean S.L., Beck J.P., Woolley M.L., Neill J.C. A preliminary investigation into the effects of antipsychotics on sub-chronic phencyclidine-induced deficits in attentional set-shifting in female rats. Behav. Brain Res. 2008, 189:152-158.
48. Minabe Y., Shirayama Y., Hashimoto K., Routledge C., Hagan J.J., Ashby C.R. Effect of the acute and chronic administration of the selective 5-HT6 receptor antagonist SB-271046 on the activity of midbrain dopamine neurons in rats: an in vivo electrophysiological study. Synapse 2004, 52:20-28.
49. Mitchell E.S., Neumaier J.F. 5-HT6 receptors: a novel target for cognitive enhancement. Pharmacol. Ther. 2005, 108:320-333.
50. Mitchell E.S., Neumaier J.F. 5-HT6 receptor antagonist reversal of emotional learning and prepulse inhibition deficits induced by apomorphine or scopolamine. Pharmacol. Biochem. Behav. 2008, 88:291-298.
51. Mohn A.R., Gainetdinov R.R., Caron M.G., Koller B.H. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 1999, 98:427-436.
52. Mork, A., Karlsson, J. J., and Arnt, J. (2010). The 5-HT6 receptor antagonist, Lu AE58054 blocks the effect of 5-HT6 receptor-stimulated modulation of extracellular neurotransmitter levels in the medial prefrontal cortex of rats. Society of Neuroscience Abstracts, 405.28.
53. Mork A., Witten L.M., Arnt J. Effect of sertindole on extracellular dopamine, acetylcholine, and glutamate in the medial prefrontal cortex of conscious rats: a comparison with risperidone and exploration of mechanisms involved. Psychopharmacology (Berl) 2009, 206:39-49.
54. Moser P.C., Hitchcock J.M., Lister S., Moran P.M. The pharmacology of latent inhibition as an animal model of schizophrenia. Brain Res. Brain Res. Rev. 2000, 33:275-307.
55. Olsen C.K., Brennum L.T., Kreilgaard M. Using pharmacokinetic-pharmacodynamic modelling as a tool for prediction of therapeutic effective plasma levels of antipsychotics. Eur. J. Pharmacol. 2008, 584:318-327.
56. Penschuck S., Flagstad P., Didriksen M., Leist M., Michael-Titus A.T. Decrease in parvalbumin-expressing neurons in the hippocampus and increased phencyclidine-induced locomotor activity in the rat methylazoxymethanol (MAM) model of schizophrenia. Eur. J. Neurosci. 2006, 23:279-284.
57. Pitsikas N., Zisopoulou S., Pappas I., Sakellaridis N. The selective 5-HT(6) receptor antagonist Ro 04-6790 attenuates psychotomimetic effects of the NMDA receptor antagonist MK-801. Behav. Brain Res. 2008, 188:304-309.
58. Pouzet B., Didriksen M., Arnt J. Effects of the 5-HT(6) receptor antagonist, SB-271046, in animal models for schizophrenia. Pharmacol. Biochem. Behav. 2002, 71:635-643.
59. Reynolds G.P., Abdul-Monim Z., Neill J.C., Zhang Z.J. Calcium binding protein markers of GABA deficits in schizophrenia - postmortem studies and animal models. Neurotox. Res. 2004, 6:57-61.
60. Roberts J.C., Reavill C., East S.Z., Harrison P.J., Patel S., Routledge C., Leslie R.A. The distribution of 5-HT(6) receptors in rat brain: an autoradiographic binding study using the radiolabelled 5-HT(6) receptor antagonist [(125)I]SB-258585. Brain Res. 2002, 934:49-57.
61. Rodefer J.S., Murphy E.R., Baxter M.G. PDE10A inhibition reverses subchronic PCP-induced deficits in attentional set-shifting in rats. Eur. J. Neurosci. 2005, 21:1070-1076.
62. Rodefer J.S., Nguyen T.N., Karlsson J.J., Arnt J. Reversal of subchronic PCP-induced deficits in attentional set shifting in rats by sertindole and a 5-HT6 receptor antagonist: comparison among antipsychotics. Neuropsychopharmacology 2008, 33:2657-2666.
63. Sams-Dodd F. Phencyclidine in the social interaction test: an animal model of schizophrenia with face and predictive validity. Rev. Neurosci. 1999, 10:59-90.
64. Schechter L.E., Lin Q., Smith D.L., Zhang G., Shan Q., Platt B., Brandt M.R., Dawson L.A., Cole D., Bernotas R., Robichaud A., Rosenzweig-Lipson S., Beyer C.E. Neuropharmacological profile of novel and selective 5-HT6 receptor agonists: WAY-181187 and WAY-208466. Neuropsychopharmacology 2008, 33:1323-1335.
65. Schotte A., Janssen P.F., Gommeren W., Luyten W.H., Van Gompel P., Lesage A.S., De Loore K., Leysen J.E. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl) 1996, 124:57-73.
66. Schreiber R., Vivian J., Hedley L., Szczepanski K., Secchi R.L., Zuzow M., van Laarhoven S., Moreau J.L., Martin J.R., Sik A., Blokland A. Effects of the novel 5-HT(6) receptor antagonist RO4368554 in rat models for cognition and sensorimotor gating. Eur. Neuropsychopharmacol. 2007, 17:277-288.
67. Skarsfeldt T. Electrophysiological profile of the new atypical neuroleptic, sertindole, on midbrain dopamine neurones in rats: acute and repeated treatment. Synapse 1992, 10:25-33.
68. Skarsfeldt T. Differential effect of antipsychotics on place navigation of rats in the Morris water maze. A comparative study between novel and reference antipsychotics. Psychopharmacology (Berl) 1996, 124:126-133.
69. Snigdha S., Neill J.C. Efficacy of antipsychotics to reverse phencyclidine-induced social interaction deficits in female rats - a preliminary investigation. Behav. Brain Res. 2008, 187:489-494.
70. Snigdha S., Neill J.C. Improvement of phencyclidine-induced social behaviour deficits in rats: involvement of 5-HT1A receptors. Behav. Brain Res. 2008, 191:26-31.
71. Tseng K.Y., Chambers R.A., Lipska B.K. The neonatal ventral hippocampal lesion as a heuristic neurodevelopmental model of schizophrenia. Behav. Brain Res. 2009, 204:295-305.
72. Upton N., Chuang T.T., Hunter A.J., Virley D.J. 5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer's disease. Neurotherapeutics 2008, 5:458-469.
73. Wang C.Z., Yang S.F., Xia Y., Johnson K.M. Postnatal phencyclidine administration selectively reduces adult cortical parvalbumin-containing interneurons. Neuropsychopharmacology 2008, 33:2442-2455.
74. Ward R.P., Dorsa D.M. Colocalization of serotonin receptor subtypes 5-HT2A, 5-HT2C, and 5-HT6 with neuropeptides in rat striatum. J. Comp. Neurol. 1996, 370:405-414.
75. Woolley M.L., Marsden C.A., Fone K.C. 5-HT6 receptors. Curr. Drug Targets 2004, 3:59-89.
76. Wünsch, A. M., Nguyen, H. Q., Guynn, L., and Rodefer, J. S. (2006). Effects of 5-HT6 antagonists on attenuating PCP-induced cognitive deficits in a rodent set-shifting (ED/ID) task. Society of Neuroscience Abstracts 264.23.
77. Zhang W., Bymaster F.P. The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D1, D2, D3, 5HT2A and muscarinic receptors. Psychopharmacology (Berl) 1999, 141:267-278.